Introducing Human Data Era, a New Serial Podcast from Amgen R&D  

Join host Ray Deshaies, Amgen’s senior vice president of Global Research, who speaks with Dr. Kári Stefánsson, M.D., founder, of deCODE genetics about the Role of Human Diversity in Progressing Precision Medicine s Amgen R&D’s next podcast series, Human Data Era,...

Multiomics study of nonalcoholic fatty liver disease

Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). Kari Stefansson CEO of deCODE genetics and senior author on the paper and Gardar...

CRTAC1 is a promising biomarker of osteoarthritis

CRTAC1 in plasma is a specific biomarker of osteoarthritis, a measure of OA risk, and a predictor of progression to joint replacements. The lack of a biomarker of osteoarthritis (OA) has hindered the development of effective therapies for this common disease. Kari...

First report from the world’s most ambitious sequencing project

Reykjavík, Iceland, July 20, 2022 – Scientists at deCODE genetics a subsidiary of Amgen together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature today. This...

25th anniversary of deCODE genetics

DeCODE genetics celebrated its 25th anniversary with a two-day conference in Reykjavik on the 18 and 18th of May. The first day was dedicated to deCODES contributions to the Study of Human Diversity over 25 years. The second day was committed to Human Diversity,...